Condition category
Eye Diseases
Date applied
20/12/2005
Date assigned
20/12/2005
Last edited
17/08/2009
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Esther Röder

ORCID ID

Contact details

Erasmus Medical Center
Department of General Practice
P.O. Box 1738
Rotterdam
3000 DR
Netherlands
+31 (0)10 4088014
e.roder@erasmusmc.nl

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

NTR284

Study information

Scientific title

Acronym

STARDROP

Study hypothesis

In comparison with placebo SLIT will lead to a clinical relevant symptom reduction in 6 to 18 years old children with a rhinoconjunctivitis due to grass pollen allergy.

Ethics approval

Received from local medical ethics committee

Study design

Randomised triple blind placebo controlled parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type

Treatment

Patient information sheet

Condition

Rhinoconjunctivitis, Grass pollen allergy

Intervention

Active treatment:
Oralgen® Grass Pollen (9.500 BU/ml), consists of a mixture of aqueous extracts of the pollen of five grass pollen species in a glycerinated isotonic phosphate buffered solution.

The following grass pollen species are included:
1. Phleum pratense: Timothy, (Timotheegras)
2. Dactylis glomerate: Orchard grass, (Kropaar)
3. Anthoxantum odoratum: Vernal grass, Sweet grass, (Reukgras)
4. Holcus lanatus: Velvet grass, (Echte witbol)
5. Lolium perenne: Ryegrass, Perennial grass, (Engels raaigras)

Other ingredients include sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate, glycerol and water.

Control treatment:
The placebo consists of the non-active excipients, as mentioned above. Placebo treatment group.
The placebo consists of the non-active excipients, as mentioned above. Placebo treatment will be delivered in such a way that neither patients nor investigators or other research personnel can make a distinction between verum and placebo vials.

Dose schedule:
The treatment is divided in two phases: a dose escalation phase of 20 days, and a maintenance phase of 2 years. Treatment starts on day 1 with a single drop (one drop 0.05 ml = 475 BU); the dose is increased with one drop per day until day 20 (20 drops = l ml = 9.500 BU). The maintenance dose is 20 drops (= 9500 BU) twice weekly.

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

The primary endpoint is the mean daily total symptom score as administered by the patient in the second year of treatment during the period May-August on the days at which grass-pollen counts exceeded a predefined cut-off level. This second year can be replaced by the first year outcomes depending on the resulting pollen counts (see below).

Cut-off level grass pollen count.
For each day during the period May-August the grass-pollen count will be determined using data from the station in Leiden. The median value of these pollen counts will be used as cut-off-level in this analysis. Subsequently for each study day it will be determined whether the actual pollen count was above or below the resulting cut-off-level.

Year of evaluation.
In case during the second year, in the period of May 15 until June 30, the mean daily seasonal grass pollen count is less than or equal to 25 pollen grains/m3, while this limit was exceeded for the first year, the first year diary outcomes will be considered as primary and will replace the second year diary outcomes.
The replacement for individual patients of the second year by the first year diary outcomes will also take place in case the diary during the second year is insufficiently completed (less than 50% of relevant days) while at the same time the first year is not a lost season.

Efficacy is measured by patient-assessed symptom scores.
Main allergic symptoms are considered to be the following: sneezing; itching nose; watery running nose; nasal blockage; itching eyes.
The intensity of these symptoms is subjectively assessed according to a grading scale: 0 = no complaints; 1 = minor complaints; 2 = moderate complaints; 3 = serious complaints; i.e. the maximal score amounts to a value of 15.
The period of measurement will be May till August in the years 2002 and 2003; 2003 and 2004. During these periods symptom scores are assessed daily by the patient and recorded in the patient diary.

Secondary outcome measures

1. Investigator assessed symptom-scores during the planned visits in the flowering season
2. Number of medication free days
3. Rescue medication
4. Generic quality of life assessment with COOP/WONCA charts
5. Rhinitis specific quality of life assessment (Juniper)
6. Lower airway symptoms
7. Adverse-effects
8. Compliance

Overall trial start date

01/09/2001

Overall trial end date

01/09/2004

Reason abandoned

Eligibility

Participant inclusion criteria

1. Age; between 6 and 18 years.
2. Patients known in general practice with documented clinical history of grass pollen allergy with moderate disease intensity as retrospectively derived from the use of symptomatic allergy medication during the previous grass pollen season i.e. regular use of cromoglycates as nasal spray and/or eye drops and/or regular use of anti-histamine tablets or sprays and/or limited use of local acting or systemically administered corticosteroids
3. Moderate grass pollen allergy as retrospectively derived from allergy symptom scores during the previous grass pollen season. Therefore, the following 5 symptoms are evaluated for the previous season:
3.1 Nasal blockage
3.2 Sneezing
3.3 Itching nose
3.4 Watery running nose
3.5 Itching eyes
The intention of each of these 5 symptoms is (subjectively) assessed by the patient according to a grading scale: 0 = no complaints; 1 = minor complaints; 2 = moderate complaints; 3 = serious complaints (maximal total value is 15). At conclusion the retrospective total value should amount at least a value of 5.
4. Positive grass pollen specific IgE Rast test i.e. RAST score = 2+

Participant type

Patient

Age group

Child

Gender

Both

Target number of participants

204

Participant exclusion criteria

1. Clinical history of severe asthmatic symptoms requiring inhalant therapy with daily pulmonary steroids during at least 3 months a year
2. Allergic sensitivity to epithelial, in case the domestic animal is present in the family home
3. The intention to subject the patient to surgery of the nasal cavity in the course of the study
4. Previous immunotherapy
5. Contraindications to sublingual immunotherapy ie:
5.1 Malignancies and serious disorders of the oral cavity
5.2 History of status asthmaticus and anaphylactic shock
5.3 Aggressively developing asthmatic symptoms
5.4 Serious chronic inflammations, chronic disorders associated with fever, particularly of the bronchial tubes
5.5 Irreversible, secondary changes in reactive organs (emphysema, bronchiectasis)
5.6 Autoimmune diseases and immunodeficiency
5.7 Concurrent therapy involving immunosuppressives
5.8 Systemic and collagen diseases
5.9 Tuberculosis of the lung and tuberculosis
5.10 Serious psychological disorders
5.11 Documented hypersensitivity to glycerol
5.12 Pregnancy
5.13 Use of beta-blockers
6. Inability to communicate in the Dutch language
7. Exposure to any investigational drug within 30 days of enrolment

Recruitment start date

01/09/2001

Recruitment end date

01/09/2004

Locations

Countries of recruitment

Netherlands

Trial participating centre

Erasmus Medical Center,
Rotterdam
3000 DR
Netherlands

Sponsor information

Organisation

Artu Biologicals Europe B.V. (Netherlands)

Sponsor details

Vijzelweg 11
Lelystad
8243 PM
Netherlands
+31 (0)320 267900
info@artu-biologicals.com

Sponsor type

Industry

Website

Funders

Funder type

Charity

Funder name

Foundation for the Prevention of Asthma (Stichting Astma Bestrijding [SAB]) (Netherlands)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2007 results in http://www.ncbi.nlm.nih.gov/pubmed/17321581

Publication citations

  1. Results

    Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R, Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care., J. Allergy Clin. Immunol., 2007, 119, 4, 892-898, doi: 10.1016/j.jaci.2006.12.651.

Additional files

Editorial Notes